Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02285985 · ClinicalTrials.gov registry record · Phase 4
Effects of Saxagliptin on Adipose Tissue Inflammation in Humans
A Phase 4 study, sponsored by Phoenix VA Health Care System.
- Completed
- Registry status
- Phase 4
- Development phase
- 103
- Enrollment target
NCT02285985 is a Phase 4 study that has completed, run by Phoenix VA Health Care System. The registered enrollment target is 103 participants.
The verdict
NCT02285985, a Phase 4 study, has completed, sponsored by Phoenix VA Health Care System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 103 participants
- Enrollment target
Study Summary
In this research study, Investigators will be comparing the effects of a medication Saxagliptin versus placebo (a similar looking pill that contains no medication) on inflammation in the body. Research Hypothesis DPP-4 inhibition by saxagliptin (ONGLYZA™) reduces adipose tissue inflammation in obese individuals and this is characterized by decreases in a) reactive oxygen species (ROS) production, b) toll-like receptors (TLR) and NF-kappa B pathway activation, c) expression of pro-inflammatory genes, d) macrophage infiltration, and e) secretion of pro-inflammatory factors.
Interventions
- DRUG Placebo
- DRUG Saxagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2013-02 |
| Est. Completion | 2019-10-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02285985
The ClinicalTrials.gov registry entry for NCT02285985 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Phoenix VA Health Care System, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02285985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02285985 about?
NCT02285985 is a clinical study titled "Effects of Saxagliptin on Adipose Tissue Inflammation in Humans". In this research study, Investigators will be comparing the effects of a medication Saxagliptin versus placebo (a similar looking pill that contains no medication) on inflammation in the body. Research Hypothesis DPP-4 inhibition by saxagliptin (ONGLYZA™) reduces adipose tissue inflammation in obes...
What is the current status of trial NCT02285985?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 103 participants. The study started on 2013-02. Estimated completion is 2019-10-12.
What interventions are being tested in trial NCT02285985?
The interventions under investigation include: Placebo (DRUG), Saxagliptin (DRUG).
Who is sponsoring clinical trial NCT02285985?
This trial is sponsored by Phoenix VA Health Care System, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.